SK C&C Turns to AI for New Drug Development | Be Korea-savvy

SK C&C Turns to AI for New Drug Development

(image: Korea Bizwire)

(image: Korea Bizwire)

SEOUL, Sept. 7 (Korea Bizwire)SK C&C Co., an IT service unit of South Korean conglomerate SK Group, said Monday it had expanded the application area of its artificial intelligence (AI)-based target identification platform to include non-alcoholic fatty liver disease.

The platform, originally intended for the development of new drugs for metabolic diseases, was developed in February in collaboration with the Gachon University Gil Hospital.

The iClue-Target Discovery for Metabolic Disease is an AI-based target identification service that explores and verifies disease-causing genes and proteins.

SK C&C expanded the service’s application area from diabetes and obesity into non-alcoholic fatty liver disease by leveraging the analysis of the latest theses data and the hospital’s OMICS data.

Non-alcoholic fatty liver disease is drawing attention from pharmaceutical companies worldwide since there is no specific treatment despite its higher occurrence rate among metabolic diseases.

The iClue-Target Discovery for Metabolic Disease provides the target correlation analysis result on the basis of five standards, including gene signal transmission path and gene expression information, for other diseases in addition to metabolic diseases.

It shows the upper-ranked target information frequently cited in the latest theses without the need to search, while automatically providing information about the correlation between the targets set by the researchers and the diseases.

Kevin Lee (

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>